CD36 and neoplasm: Flow cytometry analysis of tumor-treated BMDMs showed a decreased percentage of antitumor M1-type macrophages (CD206lowCD80high), but an increased presence of protumor M2-type macrophages (CD206highCD80low), which could be largely abrogated by CD36 deletion (Supplementary Fig. 8e, f).